endolucinbeta
itm medical isotopes gmbh - lutetium (177lu) chloride - radionuklidien kuvantaminen - terapeuttiset radiofarmaseuttiset valmisteet - endolusiinibeta on radiofarmaseuttinen prekursori, eikä sitä ole tarkoitettu suoraan potilaille. sitä on tarkoitus käyttää vain sellaisten kantajamolekyylien radioaktiiviseen merkintään, jotka on erityisesti kehitetty ja sallittu radiolabeloitavaksi lutetium (177lu) -kloridilla.
lumark
i.d.b. radiopharmacy b.v. - lutetium (177lu) chloride - radionuklidien kuvantaminen - terapeuttiset radiofarmaseuttiset valmisteet - lumark on radiofarmaseuttinen prekursori. sitä ei ole tarkoitettu suoraan potilaille. tätä lääkettä on käytettävä vain radiolabeloitavaksi kantajamolekyyleille, jotka on erityisesti kehitetty ja sallittu radiolabeloitavaksi tällä radionuklidilla.
sutent
pfizer limited - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionuklidien kuvantaminen - terapeuttiset radiofarmaseuttiset valmisteet - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
sunitinib accord
accord healthcare s.l.u. - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
buctril
bayer ag - ephedrini hydrochloridum,proxyphyllinum,phenobarbitalum - tabletti - proksifylliini ja adrenergiset lääkeaineet
everolimus stada 2.5 mg tabletti
stada arzneimittel ag stada arzneimittel ag - everolimuusi - tabletti - 2.5 mg - everolimuusi
everolimus stada 5 mg tabletti
stada arzneimittel ag stada arzneimittel ag - everolimuusi - tabletti - 5 mg - everolimuusi
everolimus stada 10 mg tabletti
stada arzneimittel ag stada arzneimittel ag - everolimuusi - tabletti - 10 mg - everolimuusi